CHICAGO -- Bumping up the dose of aflibercept (Eylea) led to prolonged treatment intervals for neovascular eye disease without a loss in efficacy or major increase in adverse events, two randomized ...
EyePoint Pharmaceuticals receives a reiterated sell rating due to ongoing clinical and commercial uncertainties despite recent progress in DME and wet AMD trials. Duravyu (EYP-1901) showed positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback